CD22 Positive clinical trials at UC Health
1 in progress, 0 open to eligible people
A Study of Experimental Inotuzumab Ozogamicin for Younger Patients With CD22 Positive B Acute Lymphoblastic Leukemia
Sorry, currently not accepting new patients, but might later
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.
at UC Davis UCLA UCSF